Phaseline

Companies › Continuity Biosciences

Continuity Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ACT-IOP-003
Implantable iontophoresis device for direct pancreatic delivery of gemcitabine
–Phase 1Pancreatic Adenocarcinoma Non-resectableAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07481383ACT-IOP-003Phase 1Pancreatic Adenocarcinoma Non-resectableOncologyAug 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.